543 related articles for article (PubMed ID: 33000490)
1. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
Liu L; Zhu M; Wang Y; Li M; Gu Y
World J Surg Oncol; 2023 Dec; 21(1):389. PubMed ID: 38114991
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
Yin W; Wang Y; Wu Z; Ye Y; Zhou L; Xu S; Lin Y; Du Y; Yan T; Yang F; Zhang J; Liu Q; Lu J
Clin Cancer Res; 2022 Sep; 28(17):3677-3685. PubMed ID: 35713517
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Ding Y; Mo W; Xie X; Wang O; He X; Zhao S; Gu X; Liang C; Qin C; Ding K; Yang H; Ding X
Oncol Res Treat; 2023; 46(7-8):303-311. PubMed ID: 37302393
[TBL] [Abstract][Full Text] [Related]
6. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
Li Q; Wang Y; Zhu M; Gu Y; Tang Y
Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
[TBL] [Abstract][Full Text] [Related]
7. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
[TBL] [Abstract][Full Text] [Related]
12. Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Liu Z; Wang C; Chen X; Zhu J; Sun X; Xia Q; Lu Z; Qiao J; Zhou Y; Wang H; Wang Y; Yan M
Eur J Cancer; 2022 Apr; 165():157-168. PubMed ID: 35235873
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
14. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
Front Oncol; 2022; 12():855512. PubMed ID: 35463365
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
16. A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q; Qi X; Tang P; Fan L; Chen L; Wang S; Liang Y; Hu Y; Wang M; Ren L; Zhang G; Tan X; Yuan L; Du J; Wu X; Wang M; Che H; Lv P; Chen D; Hu J; Li Q; Zhang Y; Yang K; Zhong Y; Chen C; Zhou Z; Qian L; Zhang J; Ma M; Sun Y; Zhang Y; Jiang J
MedComm (2020); 2023 Dec; 4(6):e435. PubMed ID: 38077249
[TBL] [Abstract][Full Text] [Related]
17. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.
Tian C; Wang M; Liu H; Liu J; Xu M; Ma L
Ir J Med Sci; 2023 Jun; 192(3):1041-1049. PubMed ID: 35829909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]